Biology of Anti-TNF Agents in Immune-Mediated Inflammatory Diseases: Therapeutic Implications
- 14 October 2016
- journal article
- review article
- Published by Taylor & Francis in Immunotherapy
- Vol. 8 (12) , 1427-1436
Abstract
Biologics are increasingly being used to modify the course of immune-mediated inflammatory diseases. Some main agents are monoclonal antibodies and a fusion-protein that target TNF. This group includes adalimumab, infliximab, certolizumab pegol, golimumab and etanercept. Although the efficacy of anti-TNFs is supported by numerous randomized clinical trials, their pharmacokinetics depend on many factors, in particular immunogenicity, which can cause marked and rapid clearance and a consequent decrease in efficacy. Kinetics involve receptors that recognize the Fc fragment of the antibody and are responsible for various processes. Pharmacological advances permit optimizing the pharmacokinetics of anti-TNFs. In this review, we examine the kinetics of anti-TNF biologics, and consequent therapeutic implications, and overview some latest developments in the field.Keywords
This publication has 51 references indexed in Scilit:
- PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteinsProtein Engineering, Design and Selection, 2013
- The Immunogenicity of Polyethylene Glycol: Facts and FictionPharmaceutical Research, 2013
- Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritisNature Reviews Rheumatology, 2013
- Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2012
- Fc Gamma Receptor CD64 Modulates the Inhibitory Activity of InfliximabPLOS ONE, 2012
- Strategies for extended serum half-life of protein therapeuticsCurrent Opinion in Biotechnology, 2011
- FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivoProceedings of the National Academy of Sciences, 2010
- Role of chaperones and FcγR in immunogenic deathCurrent Opinion in Immunology, 2008
- Ca2+-dependent Calmodulin Binding to FcRn Affects Immunoglobulin G Transport in the Transcytotic PathwayMolecular Biology of the Cell, 2008
- Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolutionPostgraduate Medical Journal, 2007